Nuvectis Pharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company that develops precision medicines for serious unmet needs in oncology. The company focuses on novel small-molecule drug candidates, including its lead asset NXP900, an oral inhibitor of SRC family kinases (SFK) targeting proto-oncogenes c-Src and YES1 to block both catalytic and scaffolding functions in signaling pathways for solid tumors; and NXP800, a GCN2 kinase activator that induces integrated stress response and cap-dependent protein translation inhibition for ARID1a-mutated cancers. NXP900 advances in Phase 1b trials as monotherapy for YES1/SRC-driven solid tumors and in combination for ALK-positive/EGFR-mutated NSCLC, following successful completion of Phase 1a dose escalation and drug-drug interaction studies showing favorable safety with mild gastrointestinal effects and over 90% kinase inhibition at higher doses; NXP800 progresses in Phase 1b for platinum-resistant ARID1a-mutated ovarian cancer with Fast Track and Orphan Drug Designations, plus an investigator-sponsored trial in cholangiocarcinoma with Orphan Drug Designation. Founded in 2020 and headquartered in Fort Lee, New Jersey, the company, formerly Centry Pharma, Inc., operates primarily in the United States with a global development focus on oncology patient populations. Recent developments include discontinuation of NXP800 expansion in ovarian cancer after mixed Phase 1b data showing 33% response rate and 100% disease control in evaluable patients, with reprioritization toward NXP900 as the lead candidate and exploration of NXP800 in endometrial and prostate cancers; strengthening of cash position to $39 million pro forma as of June 2025 via at-the-market equity sales to a healthcare investor, funding operations into late 2027; poster presentations at the 2025 AACR-NCI-EORTC conference supporting NXP900's biomarker strategy; and Q3 2025 financials reflecting $7.5 million net loss amid pipeline investment.
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy?
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights